Source-grounded facts extracted from Foghorn Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2026.
“On May 7, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2026.”
Foghorn Therapeutics Inc. reported financial results for year ended December 31, 2025.
“On March 11, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the year ended December 31, 2025.”
Neil J. Gallagher was appointed as Director at Foghorn Therapeutics Inc..
“appointed Neil J. Gallagher, M.D., Ph.D. to the Board, effective May 1, 2025.”
Stuart Duty was appointed as Director at Foghorn Therapeutics Inc..
“appointed Stuart Duty to the Board, effective May 1, 2025.”
Foghorn Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).
“January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee requirements as set forth in Nasdaq Listing Rule 5605. Nasdaq Listing Rule 5605 requires, among other things, that each listed company must have an audit committee comprised of at least three members, each of whom must meet certain independence and other qualifications as set forth in such rule. As a result of the previously reported resignation of Adam M. Koppel, M.D., Ph.D. f”
Foghorn Therapeutics Inc. received a nasdaq deficiency notice notice regarding audit committee.
“January 23, 2025, Foghorn Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (the “Nasdaq”) notifying the Company that it no longer complies with Nasdaq’s audit committee”
Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.
“On May 6, 2024, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2024.”
Stephen DiPalma departed as Interim Chief Financial Officer at Foghorn Therapeutics Inc..
“In connection with Mr. Humer’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, will cease to serve in such roles.”
Kristian F. Humer was appointed as Chief Financial Officer at Foghorn Therapeutics Inc..
“On April 16, 2024, Foghorn Therapeutics Inc. (the “Company”) announced that Kristian F. Humer had been appointed to serve as the Company’s Chief Financial Officer, effective immediately.”
Foghorn Therapeutics Inc. reported the year ended December 31, 2023 results: revenue $34.2 million.
“three discovery programs using Foghorn’s proprietary Gene Traffic Control platform. Full Year 2023 Financial Highlights • Collaboration Revenues . Collaboration revenues were $34.2 million for the year ended December 31, 2023, compared to $19.2 million for the year ended December 31, 2022. The increase year-over-year was primarily driven by revenue recognized under”
Stephen J. DiPalma was appointed as Treasurer and interim Chief Financial Officer at Foghorn Therapeutics Inc..
“On January 16, 2024, the Board of Directors of Foghorn Therapeutics Inc. (the “Company”) appointed Stephen J. DiPalma as Treasurer and interim Chief Financial Officer (“CFO”), effective immediately.”
Allan Reine resigned as Chief Financial Officer at Foghorn Therapeutics Inc..
“Allan Reine, M.D. notified Foghorn Therapeutics Inc. (the "Company") of his decision to resign as Chief Financial Officer, effective January 16, 2024, to pursue other opportunities.”
Foghorn Therapeutics Inc. reported quarter ended September 30, 2023 results: revenue $17.5 million, net income $14.3 million.
“$259.9 million in c ash, cash equivalents and marketable securities, which provides cash runway into the first half of 2026 . • Collaboration Revenues. Collaboration revenue was $17.5 million for the three months ended September 30, 2023, compared to $6.6 million for the three months ended September 30, 2022. The increase year-over-year was primarily driven by revenue”
Foghorn Therapeutics Inc. terminated Research Collaboration and Exclusive License Agreement with Merck Sharp & Dohme Corp. valued at $20 million received under the Agreement (effective 2023-11-07).
“On August 9, 2023, Foghorn Therapeutics Inc. (the “Company”) received notice from Merck Sharp & Dohme Corp. (“Merck”) that Merck is terminating the Research Collaboration and Exclusive License Agreement between the Company and Merck, dated as of July 2, 2020 (the “Agreement”). The termination of the Agreement will be effective as of November 7, 2023.”
Foghorn Therapeutics Inc. reported the quarter ended June 30, 2023 results: revenue $5.6 million, net income $29.5 million.
“Collaboration revenue was $5.6 million for the three months ended June 30, 2023, compared to $4.5 million for the three months ended June 30, 2022.”
Foghorn Therapeutics Inc. shareholders approved Ratification of selection of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-21 meeting.
“Stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the voting included 31,282,179 votes for, 858 votes against and 9,849 abstentions. There were no broker non-votes regarding this proposal.”
Foghorn Therapeutics Inc. shareholders approved Election of three Class III directors at the 2023-06-21 meeting.
“Director Nominee Votes For Votes Against Abstentions Douglas G. Cole, M.D. 19,470,509 2,142,125 32,149 Balkrishan (Simba) Gill, Ph.D. 21,481,572 144,160 19,051 B. Lynne Parshall 21,600,133 25,599 19,051 There were 9,648,103 broker non-votes regarding the election of directors.”
Foghorn Therapeutics Inc. reported the quarter ended March 31, 2023 results: revenue $5.3 million, net income $30.5 million.
“First Quarter 2023 Financial Highlights • Strong Balance Sheet and Cash Runway. As of March 31, 2023, the Company had $316.0 million in cash, cash equivalents and marketable securities, which provides a cash runway into the second half of 2025 . • Collaboration Revenues. Collaboration revenue was $5.3 million for the three months ended March 31, 2023, compared to $3.9 million for the three months ended March 31, 2022. The increase year-over-year was primarily driven by revenue recognized under the Lilly collaboration agreement. • Research and Development Expenses. Research and development expenses were $30.0 million for the three months ended March 31, 2023, compared to $24.5 million for the three months ended March 31, 2022. This increase was primarily due to costs associated with continued investment in R&D personnel and platform and early-stage research investments. • General and Administrative Expenses. General and administrative expenses were $8.6 million for the three months ende”
Foghorn Therapeutics Inc.: Amended and restated bylaws to address universal proxy rules under Rule 14a-19 (effective 2023-03-07).
“On March 7, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards and a periodic review of the Company's bylaws, the Company's board of directors approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became immediately effective.”
Foghorn Therapeutics Inc. reported quarter ended September 30, 2022 results: revenue $6.6 million.
“Collaboration revenues were $6.6 million for the third quarter of 2022 compared to $0.1 million for the third quarter of 2021.”
Thomas J. Lynch Jr., MD was elected as Class I Director at Foghorn Therapeutics Inc..
“On October 27, 2022, the Board of Directors (the “Board”) of Foghorn Therapeutics Inc. (the “Company”), upon the recommendation of the Board’s Nominating and Corporate Governance Committee, elected Thomas J. Lynch Jr., MD to the Board as a Class I Director with a term to expire at the 2024 annual meeting of stockholders.”
Cigall Kadoch resigned as member of the Board of Directors at Foghorn Therapeutics Inc..
“On August 31, 2022, Cigall Kadoch, Ph.D., resigned from her position as a member of the Board of Directors of Foghorn Therapeutics Inc. (the “Company”), effective immediately.”
B. Lynne Parshall was elected as Class III Director at Foghorn Therapeutics Inc..
“elected B. Lynne Parshall to the Board as a Class III Director”
Steven Bellon was appointed as Chief Scientific Officer at Foghorn Therapeutics Inc..
“On this same date, the Company announced that Steven Bellon, PhD. had been appointed to serve as the Company’s Chief Scientific Officer, effective as of January 10, 2022.”
Carl Decicco departed as Chief Scientific Officer at Foghorn Therapeutics Inc..
“Dr. Decicco will step down from his position as Chief Scientific Officer of the Company effective as of January 10, 2022”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.